ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with
Approval broadens indication for Daiichi Sankyo and AstraZeneca’s ENHERTU to earlier use in metastatic breast cancerBased on groundbreaking DESTINY-Breast03 results showing ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)...